NRx Pharmaceuticals Presents Efficacy of IV Ketamine for Depression Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: Newsfilter
- Significant Findings: Among 8,224 patients treated with IV ketamine, 34% achieved remission compared to only 26% in the 1,830 patients treated with intranasal esketamine, indicating a clear efficacy advantage for IV ketamine.
- Clinical Data Support: The study revealed a response rate of 63% for IV ketamine patients versus 58% for those on intranasal esketamine, suggesting that IV ketamine may offer superior treatment responses in clinical settings, potentially influencing future treatment decisions.
- Policy Context Impact: This research underscores the importance of Real World Evidence (RWE) in drug approvals for depression, aligning with recent White House Executive Orders and Congressional appropriations language, which may facilitate market access for related medications.
- Future Outlook: NRx Pharmaceuticals' CEO expressed anticipation for results from larger confirmatory studies, which will provide stronger support for the clinical application of IV ketamine and further advance the company's strategic development in mental health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXP
Wall Street analysts forecast NRXP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.980
Low
25.00
Averages
37.67
High
48.00
Current: 3.980
Low
25.00
Averages
37.67
High
48.00
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NRx Pharmaceuticals Presents Efficacy of IV Ketamine for Depression Treatment
- Significant Findings: Among 8,224 patients treated with IV ketamine, 34% achieved remission compared to only 26% in the 1,830 patients treated with intranasal esketamine, indicating a clear efficacy advantage for IV ketamine.
- Clinical Data Support: The study revealed a response rate of 63% for IV ketamine patients versus 58% for those on intranasal esketamine, suggesting that IV ketamine may offer superior treatment responses in clinical settings, potentially influencing future treatment decisions.
- Policy Context Impact: This research underscores the importance of Real World Evidence (RWE) in drug approvals for depression, aligning with recent White House Executive Orders and Congressional appropriations language, which may facilitate market access for related medications.
- Future Outlook: NRx Pharmaceuticals' CEO expressed anticipation for results from larger confirmatory studies, which will provide stronger support for the clinical application of IV ketamine and further advance the company's strategic development in mental health.
See More
NRx Pharmaceuticals Closes $22.3 Million Public Offering
- Successful Offering: NRx Pharmaceuticals has successfully closed a public offering raising approximately $22.3 million at a price of $3.50 per share, reflecting market confidence in its future growth, with proceeds earmarked for operational support and expansion.
- Clear Use of Funds: The net proceeds from the offering will be utilized for working capital and general corporate purposes, aimed at advancing the company's research and development efforts in therapeutics for central nervous system disorders, particularly for suicidal depression.
- Leadership Remarks: CEO Jonathan Javitt expressed gratitude to investors for their trust and emphasized the company's commitment to developing lifesaving drugs, especially in light of the alarming statistic that an American dies by suicide every 11 minutes.
- Regulatory Compliance: The offering was conducted under an effective registration statement approved by the SEC on December 22, 2025, ensuring the company's compliance within legal frameworks, thereby enhancing investor confidence in its transparency and legitimacy.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
NRx Pharmaceuticals Announces Pricing of Public Offering
- Public Offering Pricing: NRx Pharmaceuticals announced the pricing of 5.71 million shares at $3.50 each, with gross proceeds expected to be around $20 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The company granted underwriters a 30-day option to purchase an additional 857,142 shares, a strategy that could enhance the offering size and bolster market confidence.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, aimed at supporting the company's ongoing growth and operational expansion, reflecting a proactive stance towards future development.
- Closing Timeline: The public offering is expected to close on June 4, 2026, marking a significant step in the company's capital market activities and strategic execution.
See More
NRx Pharmaceuticals Proposes Underwritten Public Offering
- Public Offering Announcement: NRx Pharmaceuticals has proposed an underwritten public offering of common stock at a par value of $0.001 per share, which is expected to provide working capital and general corporate purposes; however, this announcement led to a 22% drop in share price during overnight trading.
- Underwriter Option: The underwriters will be granted a 30-day option to purchase an additional 15% of the common stock sold in the offering, a strategy aimed at enhancing market acceptance and liquidity of the issuance.
- Drug Development Progress: NRx is developing NRX-100, a preservative-free intravenous ketamine candidate that has received Fast Track designation from the FDA for treating suicidal ideation in depression and bipolar depression, indicating its potential in the mental health sector.
- Market Reaction: NRXP closed at $4.62 on Tuesday, but shares fell to $3.58 in the overnight market, reflecting a 22.51% decline, which indicates investor concerns regarding the offering and uncertainty about the company's future prospects.
See More
NRx Pharmaceuticals Plans Underwritten Public Offering of Common Stock
- Public Offering Announcement: NRx Pharmaceuticals has announced plans for an underwritten public offering of common stock, with the underwriter granted a 30-day option to purchase up to an additional 15% of shares, indicating the company's intent to raise capital in the market.
- Use of Proceeds: The proceeds from this offering are intended for working capital and general corporate purposes, highlighting the company's strategy to enhance financial flexibility in the current market environment to support future growth.
- Underwriting Team: BTIG is acting as the lead bookrunner, with Lucid Capital Markets serving as the joint bookrunning manager, reflecting the company's professionalism and market confidence in selecting its underwriters.
- Cautious Market Reaction: Analysts have rated NRx Pharmaceuticals as a 'Sell' due to failures with ZYESAMI and NRX-101 and uncertainties in the depression market, which may negatively impact the company's stock price.
See More
NRx Pharmaceuticals Presents Efficacy of IV Ketamine for Depression Treatment
- Significant Findings: Among 8,224 patients treated with IV ketamine, 34% achieved remission compared to only 26% in the 1,830 patients treated with intranasal esketamine, indicating a clear efficacy advantage for IV ketamine.
- Clinical Data Support: The study revealed a response rate of 63% for IV ketamine patients versus 58% for those on intranasal esketamine, suggesting that IV ketamine may offer superior treatment responses in clinical settings, potentially influencing future treatment decisions.
- Policy Context Impact: This research underscores the importance of Real World Evidence (RWE) in drug approvals for depression, aligning with recent White House Executive Orders and Congressional appropriations language, which may facilitate market access for related medications.
- Future Outlook: NRx Pharmaceuticals' CEO expressed anticipation for results from larger confirmatory studies, which will provide stronger support for the clinical application of IV ketamine and further advance the company's strategic development in mental health.
See More
NRx Pharmaceuticals Closes $22.3 Million Public Offering
- Successful Offering: NRx Pharmaceuticals has successfully closed a public offering raising approximately $22.3 million at a price of $3.50 per share, reflecting market confidence in its future growth, with proceeds earmarked for operational support and expansion.
- Clear Use of Funds: The net proceeds from the offering will be utilized for working capital and general corporate purposes, aimed at advancing the company's research and development efforts in therapeutics for central nervous system disorders, particularly for suicidal depression.
- Leadership Remarks: CEO Jonathan Javitt expressed gratitude to investors for their trust and emphasized the company's commitment to developing lifesaving drugs, especially in light of the alarming statistic that an American dies by suicide every 11 minutes.
- Regulatory Compliance: The offering was conducted under an effective registration statement approved by the SEC on December 22, 2025, ensuring the company's compliance within legal frameworks, thereby enhancing investor confidence in its transparency and legitimacy.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
NRx Pharmaceuticals Announces Pricing of Public Offering
- Public Offering Pricing: NRx Pharmaceuticals announced the pricing of 5.71 million shares at $3.50 each, with gross proceeds expected to be around $20 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The company granted underwriters a 30-day option to purchase an additional 857,142 shares, a strategy that could enhance the offering size and bolster market confidence.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, aimed at supporting the company's ongoing growth and operational expansion, reflecting a proactive stance towards future development.
- Closing Timeline: The public offering is expected to close on June 4, 2026, marking a significant step in the company's capital market activities and strategic execution.
See More
NRx Pharmaceuticals Proposes Underwritten Public Offering
- Public Offering Announcement: NRx Pharmaceuticals has proposed an underwritten public offering of common stock at a par value of $0.001 per share, which is expected to provide working capital and general corporate purposes; however, this announcement led to a 22% drop in share price during overnight trading.
- Underwriter Option: The underwriters will be granted a 30-day option to purchase an additional 15% of the common stock sold in the offering, a strategy aimed at enhancing market acceptance and liquidity of the issuance.
- Drug Development Progress: NRx is developing NRX-100, a preservative-free intravenous ketamine candidate that has received Fast Track designation from the FDA for treating suicidal ideation in depression and bipolar depression, indicating its potential in the mental health sector.
- Market Reaction: NRXP closed at $4.62 on Tuesday, but shares fell to $3.58 in the overnight market, reflecting a 22.51% decline, which indicates investor concerns regarding the offering and uncertainty about the company's future prospects.
See More
NRx Pharmaceuticals Plans Underwritten Public Offering of Common Stock
- Public Offering Announcement: NRx Pharmaceuticals has announced plans for an underwritten public offering of common stock, with the underwriter granted a 30-day option to purchase up to an additional 15% of shares, indicating the company's intent to raise capital in the market.
- Use of Proceeds: The proceeds from this offering are intended for working capital and general corporate purposes, highlighting the company's strategy to enhance financial flexibility in the current market environment to support future growth.
- Underwriting Team: BTIG is acting as the lead bookrunner, with Lucid Capital Markets serving as the joint bookrunning manager, reflecting the company's professionalism and market confidence in selecting its underwriters.
- Cautious Market Reaction: Analysts have rated NRx Pharmaceuticals as a 'Sell' due to failures with ZYESAMI and NRX-101 and uncertainties in the depression market, which may negatively impact the company's stock price.
See More
